October 07, 2024
Mylan Pharmaceuticals and Novo Nordisk have asked the Patent Trial and Appeal Board to terminate Mylan's request to review whether a patent covering Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic holds up, telling the board the two sides have resolved their dispute.
August 02, 2024
Novo Nordisk is urging the Patent Trial and Appeal Board to sanction Mylan for pursuing claims to invalidate a patent covering the blockbuster diabetes and weight loss drug Ozempic in Delaware district court, despite an explicit promise not to do so.
October 04, 2023
The Patent Trial and Appeal Board on Wednesday granted Mylan's request to review whether a patent covering Novo Nordisk's blockbuster drug Ozempic holds up, just two days after clearing the Danish company from challenges to related patents.